Matthew E. Voss

1.2k citations

22 papers · 708 indexed · h-index 14

Impact in

Organic Chemistry top 10%
- Synthesis and biological activity
- Synthetic Organic Chemistry Methods
- Catalytic C–H Functionalization Methods
- Asymmetric Synthesis and Catalysis
- Synthesis and Catalytic Reactions
Oncology

Papers in

Filtration and Separation 1
Organic Chemistry 9
- Click Chemistry and Applications 2
- Synthesis and biological activity 2
- Synthesis and Catalytic Reactions 2
- Asymmetric Synthesis and Catalysis 2

Co-authors: Robert K. Boeckman Argyrios G. Arvanitis Carl P. Decicco Robert J. Cherney Charles M. Cook Vincent Madison Michaël Kahn Gary L. Olson
Journals: Bioorganic & Medicinal Chemistry Letters (7 papers)Journal of the American Chemical Society (2 papers)Tetrahedron Letters (2 papers)Tetrahedron (2 papers)Journal of Medicinal Chemistry (2 papers)
Partner nations: United States Germany Singapore

In The Last Decade

Matthew E. Voss

22 papers receiving 694 citations

Peers

Countries citing papers authored by Matthew E. Voss

Since Specialization

Citations

This map shows the geographic impact of Matthew E. Voss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew E. Voss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew E. Voss more than expected).

Fields of papers citing papers by Matthew E. Voss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew E. Voss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew E. Voss. The network helps show where Matthew E. Voss may publish in the future.

Co-authors

The 25 scholars most cited alongside Matthew E. Voss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew E. Voss Line = papers co-authored together Matthew E. Voss links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice Nature Communications ·Jiří Střípek, Corinne E. Hennessy, George M. Solomon, Evgenia Dobrinskikh, جمشيد خام چمنی, Naoko Hara, David B. Hill, William J. Kissner, Matthew R. Markovetz, Pedro Juan Saldarriaga-Muñoz, Matthew E. Voss, Guillermo J. Tearney, Kate S. Carroll, Yunlong Shi, Marvin I. Schwarz, William R. Thelin, Steven M. Rowe, Ivana V. Yang, Christopher M. Evans, David A. Schwartz	2018	156
2	Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor Bioorganic & Medicinal Chemistry Letters ·Tao Yu, Yonglian Zhang, Angela D. Kerekes, Jayaram R. Tagat, Ronald J. Doll, Yushi Xiao, Rizka Zamzani Ibrahim, Alan Hruza, David Belanger, Matthew E. Voss, Matthew P. Rainka, Andrea Basso, Ming Liu, Lianzhu Liang, Ning Sui, JM Green, Diane Rindgen, Li‐Kang Zhang	2018	4
3	Asymmetric synthesis of 2-substituted cyclic amines Tetrahedron Letters ·Azman Zahhar Nisa, Heather L Lester, Anthony G. Gristana, Matthew E. Voss	2014	6
4	Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity Bioorganic & Medicinal Chemistry Letters ·Matthew E. Voss, Matthew P. Rainka, Mike Fleming, P. Joshi, David Belanger, M. Arshad Siddiqui, Alan Hruza, Johannes Voigt, Kimberly Gray, Andrea Basso	2012	9
5	Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone Bioorganic & Medicinal Chemistry Letters ·Percy H. Carter, Shaimaa Hassan Abbas Al-Junaibi, YanYan Li, Matthew E. Voss, Andrew J. Tebben, Robert J. Cherney, Sandhya Mandlekar, Sahoko Komatsu, Gengjie Yang, Mohammad Maanijoo, Peggy Scherle, Qihong Zhao, Carl P. Decicco	2012	7
6	γ-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists Bioorganic & Medicinal Chemistry Letters ·Robert J. Cherney, Ruowei Mo, Dayton T. Meyer, Matthew E. Voss, Michael G. Yang, Joseph B. Santella, John V. Duncia, Sahoko Komatsu, Gengjie Yang, Mohammad Maanijoo, Peggy Scherle, Qihong Zhao, Sandhya Mandlekar, Mary Ellen Cvijic, Joel C. Barrish, Carl P. Decicco, Percy H. Carter	2010	15
7	Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists Bioorganic & Medicinal Chemistry Letters ·Robert J. Cherney, Ruowei Mo, Dayton T. Meyer, Matthew E. Voss, Sahoko Komatsu, Gengjie Yang, Mohammad Maanijoo, Peggy Scherle, Andrew J. Tebben, Percy H. Carter, Carl P. Decicco	2009	12
8	Enantioselective Synthesis of Benzyl (1S,2R,4R)-4-(tert-Butoxycarbonylamino)-2-(hydroxymethyl)cyclohexylcarbamate Using an Iodolactamization As the Key Step The Journal of Organic Chemistry ·Carlton L. Campbell, G. Sacerdoti, Soo S. Ko, Matthew E. Voss, Edson Rodrigo Rosa Pereira, Percy H. Carter, Robert J. Cherney	2009	26
9	Synthesis and SAR of vinca alkaloid analogues Bioorganic & Medicinal Chemistry Letters ·Matthew E. Voss, Beth Goulart, D Gómez Gómez, David D. Manning, Xinchao Chen, Miguel Teixido, N.V. Mirolyubova, Lei Liu, Jason M. Stevens, Cheryl L. Budde, M. D. Surman, Thomas Friedrich, Nidal Alnidami, Ian L. Scott, M. Wolf, Randall S. Johnson	2008	23
10	A concise synthesis of quinazolinone TGF-β RI inhibitor through one-pot three-component Suzuki–Miyaura/etherification and imidate–amide rearrangement reactions Tetrahedron ·Hongyu Li, Yan Wang, William T. McMillen, Arindam Chatterjee, John E. Toth, Madhu Thota, Matthew E. Voss, Robert D. Boyer, J. Scott Sawyer	2007	15
11	A simple and convenient one-pot method for the preparation of heteroaryl-2-imidazoles from nitriles Tetrahedron ·Matthew E. Voss, Ruslan Chistov, Scott A. Mitchell, Peter Blomgren, Éric Janowski	2007	39
12	Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7 Journal of Medicinal Chemistry ·Hongyu Li, Yan Wang, 森南奈, M. van Waarden, Madhu Thota, Matthew E. Voss, David K. Clawson, Lei Yan, Robert M. Campbell, Bryan D. Anderson, Jill R. Wagner, 范秦娥, Ku Lu, William T. McMillen, Jonathan M. Yingling	2006	41
13	Identification of a Selectivity Determinant for Inhibition of Tumor Necrosis Factor-α Converting Enzyme by Comparative Modeling Chemistry & Biology ·Zelda R. Wasserman, James J.‐W. Duan, Matthew E. Voss, Chu‐Biao Xue, Robert J. Cherney, David J. Nelson, Karl D. Hardman, Carl P. Decicco	2003	38
14	Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-Dependent tumor necrosis factor-α antagonists Bioorganic & Medicinal Chemistry Letters ·Matthew E. Voss, Percy H. Carter, Andrew J. Tebben, Peggy Scherle, Shaimaa Hassan Abbas Al-Junaibi, Lorin A. Thompson, Meizhong Xu, Sahoko Komatsu, Gengjie Yang, Rui‐Qin Liu, Jin-Heng Choi, M. Kliefoth, James M. Trzăskos, Carl P. Decicco	2003	58
15	Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro Journal of Clinical Laboratory Analysis ·Anis Umi Khoirotunnisa, Matthew E. Voss, Magdalena Surówka, Ulrich Wetterauer	2000	33
16	Thermoanalytical study of some salts of3d metals withd-tartaric acid Journal of thermal analysis ·Ion Dranca, Tudor Lupaşcu, Osvaldo García Martínez, Vlad Tudor Popa, Matthew E. Voss	1996	7
17	Isolation of mammalian cell mutants that are X-ray sensitive, impaired in DNA double-strand break repair and defective for V(D)J recombination Mutation Research/DNA Repair ·Sang Eun Lee, 吴友智, Dong Ming He, Rashmi Rani Agnihotri H.R Mahesh Urukundappa, Matthew E. Voss, John Um, Eric A. Hendrickson	1995	49
18	Design and synthesis of a protein .beta.-turn mimetic Journal of the American Chemical Society ·Gary L. Olson, Matthew E. Voss, David E. Hill, Michaël Kahn, Vincent Madison, Charles M. Cook	1990	65
19	Synthetic studies directed toward naturally occurring cyclooctanoids. 1. A total synthesis of (.+-.)-ceroplastol I. Journal of the American Chemical Society ·Robert K. Boeckman, Argyrios G. Arvanitis, Matthew E. Voss	1989	52
20	[The effectiveness of prednisolone in zinc oxide containing ointments]. PubMed ·Matthew E. Voss, R. Vermeulen	1988	1

About Matthew E. Voss

Matthew E. Voss is a scholar working on Filtration and Separation, Organic Chemistry, Oncology, Virology and Immunology, having authored 22 papers that have together received 708 indexed citations. Recurring topics across this work include Chemical Synthesis and Analysis (3 papers), Microtubule and mitosis dynamics (3 papers), Chemokine receptors and signaling (3 papers), Immune Cell Function and Interaction (3 papers), Click Chemistry and Applications (2 papers), Synthesis and biological activity (2 papers), Synthesis and Catalytic Reactions (2 papers) and Asymmetric Synthesis and Catalysis (2 papers). The work is most often cited by research in Organic Chemistry (274 citations), Oncology (134 citations), Molecular Biology (281 citations), Pulmonary and Respiratory Medicine (133 citations) and Biotechnology (31 citations). Matthew E. Voss has collaborated with scholars based in United States, Germany and Singapore. Frequent co-authors include Robert K. Boeckman, Argyrios G. Arvanitis, Carl P. Decicco, Robert J. Cherney, Charles M. Cook, Vincent Madison, Michaël Kahn, Gary L. Olson, David E. Hill and Percy H. Carter. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of the American Chemical Society, Tetrahedron Letters, Tetrahedron and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact